Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Oct 1 2010

Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

Intra-Cellular Therapies presented preclinical data at the 2nd World Parkinson Congress held in Glasgow, Scotland, demonstrating ITI-002 was effective in improving motor and non-motor behaviors relevant to the treatment of Parkinson's disease. In well-established pre-clinical models of PD, ITI-002 was shown to restore normal motor function when given in combination with L-DOPA; ITI-002 increased the effectiveness of a sub-threshold and a sub-maximal dose of L-DOPA when the compounds were co-administered in unilaterally 6-hydroxy dopamine-lesioned or reserpine-treated mice. This combination resulted in a full restoration of the affected limb use and a re-establishment of normal mobility. ITI-002 also reversed the akinesia and catalepsy induced by the dopamine receptor antagonist haloperidol. In other pre-clinical models, ITI-002 was shown to improve cognitive performance and to increase daytime wakefulness without causing psychomotor stimulation.

"We are pleased to have demonstrated the ability of ITI-002 to improve motor and non-motor behaviors in pre-clinical models relevant to Parkinson's disease. These data suggest ITI-002 may be useful in prolonging the effectiveness and lowering the doses of dopamine replacement therapies, thereby providing for full restoration of motor function without causing troubling side effects in patients with Parkinson's Disease," stated Sharon Mates, Chief Executive Officer of Intra-Cellular Therapies.  "Since ITI-002 acts by enhancing intra-cellular dopamine signaling, ITI-002 also may be useful as a stand-alone treatment early in this disease when residual dopamine is still present.  In addition, patients with Parkinson's disease often suffer co-morbidly with dementia and excessive day time sleepiness. We believe that ITI-002 will be uniquely effective in treating these non-motor complications that are associated with Parkinson's disease."